Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B

Frederieke M. Brouwers, Sven Gläsker, Amanda F. Nave, Alexander Vortmeyer, Irina Lubensky, Steven Huang, Mones S. Abu-Asab, Graeme Eisenhofer, Robert J. Weil, Deric M. Park, W. Marston Linehan, Karel Pacak, Zhengping Zhuang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Pheochromocytomas are catecholamine-producing tumors that can occur in the context of von Hippel-Lindau syndrome (VHL) and multiple endocrine neoplasia type 2 (MEN2). Pheochromocytomas in these two syndromes differ in histopathological features, catecholamine metabolism, and clinical phenotype. To further investigate the nature of these differences, we compared the global protein expressions of 8 MEN2A-associated pheochromocytomas with 11 VHL-associated pheochromocytomas by two-dimensional gel electrophoresis proteomic profiling followed by sequencing and identification of differentially expressed proteins. Although both types of pheochromocytoma shared similarities in their protein expression patterns, the expression of several proteins was distinctly different between VHL- and MEN2A-associated pheochromocytomas. We identified several of these differentially expressed proteins. One of the proteins with higher expression in MEN2-associated tumors was chromogranin B, of which the differential expression was confirmed by western blot analysis. Our results expand the evidence for proteomic differences between these two tumor entities, and suggest that VHL-associated pheochromocytomas may be deficient in fundamental machinery for catecholamine storage. In light of these new findings, as well as existing evidence for differences between both types of pheochromocytomas, we propose that these tumors may have different developmental origins.

Original languageEnglish (US)
Pages (from-to)463-471
Number of pages9
JournalEndocrine-Related Cancer
Volume14
Issue number2
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Chromogranin B
Multiple Endocrine Neoplasia Type 2a
von Hippel-Lindau Disease
Pheochromocytoma
Proteomics
Catecholamines
Proteins
Neoplasms
Electrophoresis, Gel, Two-Dimensional
Western Blotting
Phenotype

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. / Brouwers, Frederieke M.; Gläsker, Sven; Nave, Amanda F.; Vortmeyer, Alexander; Lubensky, Irina; Huang, Steven; Abu-Asab, Mones S.; Eisenhofer, Graeme; Weil, Robert J.; Park, Deric M.; Linehan, W. Marston; Pacak, Karel; Zhuang, Zhengping.

In: Endocrine-Related Cancer, Vol. 14, No. 2, 01.06.2007, p. 463-471.

Research output: Contribution to journalArticle

Brouwers, FM, Gläsker, S, Nave, AF, Vortmeyer, A, Lubensky, I, Huang, S, Abu-Asab, MS, Eisenhofer, G, Weil, RJ, Park, DM, Linehan, WM, Pacak, K & Zhuang, Z 2007, 'Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B', Endocrine-Related Cancer, vol. 14, no. 2, pp. 463-471. https://doi.org/10.1677/ERC-06-0038
Brouwers, Frederieke M. ; Gläsker, Sven ; Nave, Amanda F. ; Vortmeyer, Alexander ; Lubensky, Irina ; Huang, Steven ; Abu-Asab, Mones S. ; Eisenhofer, Graeme ; Weil, Robert J. ; Park, Deric M. ; Linehan, W. Marston ; Pacak, Karel ; Zhuang, Zhengping. / Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. In: Endocrine-Related Cancer. 2007 ; Vol. 14, No. 2. pp. 463-471.
@article{3ff4a889b7fb4fbbaed63c83299f6a33,
title = "Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B",
abstract = "Pheochromocytomas are catecholamine-producing tumors that can occur in the context of von Hippel-Lindau syndrome (VHL) and multiple endocrine neoplasia type 2 (MEN2). Pheochromocytomas in these two syndromes differ in histopathological features, catecholamine metabolism, and clinical phenotype. To further investigate the nature of these differences, we compared the global protein expressions of 8 MEN2A-associated pheochromocytomas with 11 VHL-associated pheochromocytomas by two-dimensional gel electrophoresis proteomic profiling followed by sequencing and identification of differentially expressed proteins. Although both types of pheochromocytoma shared similarities in their protein expression patterns, the expression of several proteins was distinctly different between VHL- and MEN2A-associated pheochromocytomas. We identified several of these differentially expressed proteins. One of the proteins with higher expression in MEN2-associated tumors was chromogranin B, of which the differential expression was confirmed by western blot analysis. Our results expand the evidence for proteomic differences between these two tumor entities, and suggest that VHL-associated pheochromocytomas may be deficient in fundamental machinery for catecholamine storage. In light of these new findings, as well as existing evidence for differences between both types of pheochromocytomas, we propose that these tumors may have different developmental origins.",
author = "Brouwers, {Frederieke M.} and Sven Gl{\"a}sker and Nave, {Amanda F.} and Alexander Vortmeyer and Irina Lubensky and Steven Huang and Abu-Asab, {Mones S.} and Graeme Eisenhofer and Weil, {Robert J.} and Park, {Deric M.} and Linehan, {W. Marston} and Karel Pacak and Zhengping Zhuang",
year = "2007",
month = "6",
day = "1",
doi = "10.1677/ERC-06-0038",
language = "English (US)",
volume = "14",
pages = "463--471",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "2",

}

TY - JOUR

T1 - Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B

AU - Brouwers, Frederieke M.

AU - Gläsker, Sven

AU - Nave, Amanda F.

AU - Vortmeyer, Alexander

AU - Lubensky, Irina

AU - Huang, Steven

AU - Abu-Asab, Mones S.

AU - Eisenhofer, Graeme

AU - Weil, Robert J.

AU - Park, Deric M.

AU - Linehan, W. Marston

AU - Pacak, Karel

AU - Zhuang, Zhengping

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Pheochromocytomas are catecholamine-producing tumors that can occur in the context of von Hippel-Lindau syndrome (VHL) and multiple endocrine neoplasia type 2 (MEN2). Pheochromocytomas in these two syndromes differ in histopathological features, catecholamine metabolism, and clinical phenotype. To further investigate the nature of these differences, we compared the global protein expressions of 8 MEN2A-associated pheochromocytomas with 11 VHL-associated pheochromocytomas by two-dimensional gel electrophoresis proteomic profiling followed by sequencing and identification of differentially expressed proteins. Although both types of pheochromocytoma shared similarities in their protein expression patterns, the expression of several proteins was distinctly different between VHL- and MEN2A-associated pheochromocytomas. We identified several of these differentially expressed proteins. One of the proteins with higher expression in MEN2-associated tumors was chromogranin B, of which the differential expression was confirmed by western blot analysis. Our results expand the evidence for proteomic differences between these two tumor entities, and suggest that VHL-associated pheochromocytomas may be deficient in fundamental machinery for catecholamine storage. In light of these new findings, as well as existing evidence for differences between both types of pheochromocytomas, we propose that these tumors may have different developmental origins.

AB - Pheochromocytomas are catecholamine-producing tumors that can occur in the context of von Hippel-Lindau syndrome (VHL) and multiple endocrine neoplasia type 2 (MEN2). Pheochromocytomas in these two syndromes differ in histopathological features, catecholamine metabolism, and clinical phenotype. To further investigate the nature of these differences, we compared the global protein expressions of 8 MEN2A-associated pheochromocytomas with 11 VHL-associated pheochromocytomas by two-dimensional gel electrophoresis proteomic profiling followed by sequencing and identification of differentially expressed proteins. Although both types of pheochromocytoma shared similarities in their protein expression patterns, the expression of several proteins was distinctly different between VHL- and MEN2A-associated pheochromocytomas. We identified several of these differentially expressed proteins. One of the proteins with higher expression in MEN2-associated tumors was chromogranin B, of which the differential expression was confirmed by western blot analysis. Our results expand the evidence for proteomic differences between these two tumor entities, and suggest that VHL-associated pheochromocytomas may be deficient in fundamental machinery for catecholamine storage. In light of these new findings, as well as existing evidence for differences between both types of pheochromocytomas, we propose that these tumors may have different developmental origins.

UR - http://www.scopus.com/inward/record.url?scp=34547762713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547762713&partnerID=8YFLogxK

U2 - 10.1677/ERC-06-0038

DO - 10.1677/ERC-06-0038

M3 - Article

VL - 14

SP - 463

EP - 471

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 2

ER -